Olympus (OTCMKTS:OCPNY) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

Olympus Co. (OTCMKTS:OCPNYGet Free Report)’s share price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $18.00 and traded as low as $18.00. Olympus shares last traded at $18.00, with a volume of 400 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group upgraded Olympus to a “buy” rating in a research report on Monday, May 18th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Olympus has a consensus rating of “Buy”.

Get Our Latest Stock Analysis on OCPNY

Olympus Stock Performance

The firm’s 50-day moving average is $18.00 and its two-hundred day moving average is $18.00. The stock has a market cap of $23.15 billion, a price-to-earnings ratio of 21.95, a P/E/G ratio of 1.07 and a beta of 0.70. The company has a current ratio of 1.99, a quick ratio of 1.48 and a debt-to-equity ratio of 0.59.

About Olympus

(Get Free Report)

Olympus Corporation is a Tokyo-headquartered manufacturer specializing in medical and scientific imaging, precision optics and related equipment. The company’s medical systems business is focused on endoscopic technologies and therapeutic devices used in minimally invasive diagnosis and treatment, supplying hospitals and clinical facilities with endoscopes, visualization platforms and accessories. In addition to healthcare, Olympus serves scientific and industrial customers with microscopes, imaging systems, non-destructive testing equipment and precision measurement tools used in research, manufacturing and quality control.

In recent years the company completed a strategic refocus on healthcare and scientific solutions, divesting its consumer camera business in 2020 to concentrate resources on medical device development, services and life-science applications.

See Also

Receive News & Ratings for Olympus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olympus and related companies with MarketBeat.com's FREE daily email newsletter.